US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Polyrizon Ltd.

0.0089

-0.0037-29.37%

Volume:306.22M

Turnover:2.95M

Market Cap:60.57K

PE:- -

High:0.0111

Open:0.0110

Low:0.0085

Close:0.0126

Loading ...

Overview Company News Filings

BRIEF-Polyrizon Structures Clinical Strategy For Its Allergy Blocker Ahead Of FDA Pre-Submission Meeting

Polyrizon Ltd - Expects to Initiate Clinical Trials in U.S. and Europe in Late 2025

THOMSON REUTERS

Polyrizon Structures Clinical Strategy for Its Allergy Blocker Ahead of FDA Pre-Submission Meeting

THOMSON REUTERS

Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting

BRIEF-Polyrizon Expands Drug Delivery Innovation With Preclinical Studies For Epilepsy Rescue Treatment

Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment

Clearmind Medicine Inc - Signs Loi With Polyrizon for Intranasal Formulation for Its Psychedelic-Based Treatment Applications

THOMSON REUTERS

Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination

Polyrizon Signs Letter of Intent With Biotech Firm for Use of Its Intranasal Drug Delivery Platform

MT Newswires Live

Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments

BRIEF-Polyrizon launches preclinical studies on intranasal version of treatment to reverse opioid overdoses

Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform

THOMSON REUTERS

Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform

Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024

Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform

Polyrizon files divisional patent application with Israel Patent Office

Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform

BRIEF-Polyrizon Commences Gmp Manufacturing Preliminary Process

Polyrizon Commences Gmp Manufacturing Preliminary Process for Its Pl-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

THOMSON REUTERS

Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PLRZ/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PLRZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PLRZ\",,,,,undefined,":{"symbol":"PLRZ","market":"US","secType":"STK","nameCN":"Polyrizon Ltd.","latestPrice":0.0089,"timestamp":1747325246167,"preClose":0.0126,"halted":0,"volume":306219220,"delay":0,"floatShares":4724727,"shares":6805210,"eps":0,"marketStatus":"Trading","change":-0.0037,"latestTime":"05-15 12:07:29 EDT","open":0.011,"high":0.0111,"low":0.0085,"amount":2945341.7016209797,"amplitude":0.206349,"askPrice":0.0091,"askSize":100,"bidPrice":0.0088,"bidSize":5000,"shortable":0,"etf":0,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1747339200000},"marketStatusCode":2,"adr":0,"listingDate":1730174400000,"exchange":"NASDAQ","adjPreClose":0.0126,"preHourTrading":{"tag":"盘前","latestPrice":0.0109,"preClose":0.0126,"latestTime":"09:29 EDT","volume":35052402,"amount":422552.569926564,"timestamp":1747315799751},"postHourTrading":{"tag":"盘后","latestPrice":0.0126,"preClose":0.0126,"latestTime":"19:59 EDT","volume":42307112,"amount":544917.66972,"timestamp":1747267195938},"volumeRatio":5.032693},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PLRZ\",,,,,undefined,":{"symbol":"PLRZ","floatShares":4724727,"roa":"-26.65%","roe":"-57.83%","lyrEps":0,"volumeRatio":5.032693,"shares":6805210,"dividePrice":0,"high":0.0111,"amplitude":0.206349,"preClose":0.0126,"low":0.0085,"week52Low":0.0085,"pbRate":"0.01","week52High":4.8,"institutionHeld":0,"latestPrice":0.0089,"committee":0.960784,"eps":0,"divideRate":0,"volume":306219220,"delay":0,"ttmEps":0,"open":0.011,"prevYearClose":2.17,"prevWeekClose":0.3747,"prevMonthClose":0.31,"prevQuarterClose":0.369,"fiveDayClose":0.5908,"twentyDayClose":0.363,"sixtyDayClose":1.08},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PLRZ\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2522370846","title":"BRIEF-Polyrizon Structures Clinical Strategy For Its Allergy Blocker Ahead Of FDA Pre-Submission Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2522370846","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522370846?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:26","pubTimestamp":1743078388,"startTime":"0","endTime":"0","summary":"BRIEF-Polyrizon Structures Clinical Strategy For Its Allergy Blocker Ahead Of FDA Pre-Submission MeetingMarch 27 (Reuters) - Polyrizon Ltd PLRZ.O:POLYRIZON STRUCTURES CLINICAL STRATEGY FOR ITS ALLERGY","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nTUA7BSGDT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"gpt_icon":0},{"id":"2522882370","title":"Polyrizon Ltd - Expects to Initiate Clinical Trials in U.S. and Europe in Late 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2522882370","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522882370?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:25","pubTimestamp":1743078300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nTUA7BSGDT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ"],"gpt_icon":0},{"id":"2522737088","title":"Polyrizon Structures Clinical Strategy for Its Allergy Blocker Ahead of FDA Pre-Submission Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2522737088","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522737088?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:25","pubTimestamp":1743078300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nTUA7BSGDT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ"],"gpt_icon":0},{"id":"2522930813","title":"Polyrizon Structures Clinical Strategy for its Allergy Blocker Ahead of FDA Pre-Submission Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2522930813","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522930813?lang=en_us&edition=fundamental","pubTime":"2025-03-27 20:25","pubTimestamp":1743078300,"startTime":"0","endTime":"0","summary":"Studies to assess efficacy, safety, user experience, and nasal residence time as Company prepares for regulatory path forward. Raanana, Israel, March 27, 2025  -- Polyrizon Ltd. , a biotech company specializing in innovative intranasal hydrogels, today announced the structuring of its clinical strategy for PL-14, the Company’s proprietary intranasal allergy blocker for seasonal allergic rhinitis.The clinical strategy was updated in preparation for a planned pre-submission meeting with the U.S. Food and Drug Administration , which is expected to be followed by the initiation of clinical trials.The comprehensive clinical studies is expected to include:. A clinical study evaluating efficacy and safety under natural exposure conditions during peak allergy season. This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,”","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/polyrizon-structures-clinical-strategy-allergy-122500322.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4023","BK4600","BK4595","BK4588","PLRZ","STRK","BK4516","BK4585","HF","BK4596"],"gpt_icon":1},{"id":"2522887137","title":"BRIEF-Polyrizon Expands Drug Delivery Innovation With Preclinical Studies For Epilepsy Rescue Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2522887137","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522887137?lang=en_us&edition=fundamental","pubTime":"2025-03-26 04:06","pubTimestamp":1742933173,"startTime":"0","endTime":"0","summary":"BRIEF-Polyrizon Expands Drug Delivery Innovation With Preclinical Studies For Epilepsy Rescue TreatmentMarch 25 (Reuters) - Polyrizon Ltd PLRZ.O:POLYRIZON EXPANDS DRUG DELIVERY INNOVATION WITH PRECLIN","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q81AR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"gpt_icon":0},{"id":"2522880916","title":"Polyrizon Expands Drug Delivery Innovation with Preclinical Studies for Epilepsy Rescue Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2522880916","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522880916?lang=en_us&edition=fundamental","pubTime":"2025-03-26 04:04","pubTimestamp":1742933040,"startTime":"0","endTime":"0","summary":"According to the World Health Organization , epilepsy is a neurological condition affecting about 50 million people worldwide. Many existing therapies fail to provide adequate control of acute repetitive seizures and may come with undesirable adverse effects. The globalacute repetitive seizures market sizewas estimated at USD 3.15 billion in 2024 and is projected to grow at a CAGR of 12.7% from 2025 to 2030.According to the latest research study, the globalepilepsy treatment devices market  was valued at approximately USD 526.8 Million in 2023 and is expected to reach a value of around USD 787.3 Million by 2033, growing at a compound annual growth rate  of about 4.1% during the forecast period 2024 to 2033.“Launching this preclinical program marks an important milestone in our initiative to improve emergency treatment options for epilepsy patients,” said Tomer Izraeli, CEO of Polyrizon. “We believe our intranasal delivery platform has the potential to offer a faster, safer and more acc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/polyrizon-expands-drug-delivery-innovation-200400294.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PLRZ"],"gpt_icon":0},{"id":"2520907613","title":"Clearmind Medicine Inc - Signs Loi With Polyrizon for Intranasal Formulation for Its Psychedelic-Based Treatment Applications","url":"https://stock-news.laohu8.com/highlight/detail?id=2520907613","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520907613?lang=en_us&edition=fundamental","pubTime":"2025-03-19 19:36","pubTimestamp":1742384198,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250319:nFWN3Q20CT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CMND","PLRZ"],"gpt_icon":0},{"id":"2520907205","title":"Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination","url":"https://stock-news.laohu8.com/highlight/detail?id=2520907205","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520907205?lang=en_us&edition=fundamental","pubTime":"2025-03-19 19:35","pubTimestamp":1742384100,"startTime":"0","endTime":"0","summary":"Aiming to improve bioavailability and optimize the therapeutic effect of Clearmind’s psychedelic-based treatments. Under the terms of the non-binding LOI, Clearmind and Polyrizon will conduct research and development efforts to achieve a proof of concept for an intranasal formulation of MEAI and MEAI-PEA combinations. The companies will assess the feasibility of intranasal drug delivery, which offers several potential advantages over traditional administration methods, including faster absorption and onset of action, high bioavailability for increased therapeutic effects and enhanced patient compliance due to non-invasive administration.“This collaboration represents an exciting step forward in our efforts to continue innovating psychedelic-based treatments,” said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine. “We believe intranasal administration has the potential to improve patient outcomes by providing a faster-acting, more efficient, and user-friendly treatment option. This agree","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/clearmind-evaluate-intranasal-delivery-psychedelic-113500685.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","CMND","PLRZ"],"gpt_icon":0},{"id":"2519041408","title":"Polyrizon Signs Letter of Intent With Biotech Firm for Use of Its Intranasal Drug Delivery Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2519041408","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519041408?lang=en_us&edition=fundamental","pubTime":"2025-03-14 21:21","pubTimestamp":1741958469,"startTime":"0","endTime":"0","summary":"Polyrizon (PLRZ) said Friday that it has signed a non-binding letter of intent with an unidentified company specializing in psychedelic-based therapies to develop a novel intranasal formulation using ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PLRZ"],"gpt_icon":0},{"id":"2519098028","title":"Polyrizon Signs Non– Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=2519098028","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519098028?lang=en_us&edition=fundamental","pubTime":"2025-03-14 20:35","pubTimestamp":1741955700,"startTime":"0","endTime":"0","summary":"Raanana, Israel, March 14, 2025  -- Polyrizon Ltd.  , a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today that it has signed a non-binding Letter of Intent  with a biotech company focused on psychedelic-derived therapeutics , to develop a novel intranasal formulation for psychedelic-based treatment applications.Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and ContainTM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the na","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/polyrizon-signs-non-binding-loi-123500371.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PLRZ"],"gpt_icon":0},{"id":"2519835468","title":"BRIEF-Polyrizon launches preclinical studies on intranasal version of treatment to reverse opioid overdoses","url":"https://stock-news.laohu8.com/highlight/detail?id=2519835468","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519835468?lang=en_us&edition=fundamental","pubTime":"2025-03-13 20:10","pubTimestamp":1741867854,"startTime":"0","endTime":"0","summary":"BRIEF-Polyrizon launches preclinical studies on intranasal version of treatment to reverse opioid overdosesMarch 13 (Reuters) - Polyrizon Ltd PLRZ.O:POLYRIZON LAUNCHES PRECLINICAL STUDIES FOR INTRANAS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nTUA4JLGNN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"gpt_icon":0},{"id":"2519833173","title":"Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2519833173","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519833173?lang=en_us&edition=fundamental","pubTime":"2025-03-13 19:51","pubTimestamp":1741866660,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nTUA4JLGNN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ"],"gpt_icon":0},{"id":"2519835539","title":"Polyrizon Launches Preclinical Studies for Intranasal Naloxone to Combat Opioid Overdose Using Cutting-Edge Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2519835539","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519835539?lang=en_us&edition=fundamental","pubTime":"2025-03-13 19:51","pubTimestamp":1741866660,"startTime":"0","endTime":"0","summary":"Raanana, Israel, March 13, 2025  -- Polyrizon Ltd.  , a development stage biotech company specializing in the development of innovative intranasal hydrogels, previously announced the initiation of preclinical studies for intranasal Naloxone, a life-saving opioid overdose treatment.As previously announced, the study will be conducted in collaboration with Professor Fabio Sonvico, Associate Professor at the Department of Food and Drug of the University of Parma  a leading expert in the development of intranasal and pulmonary drug delivery solutions and a member of the Company's Scientific Advisory Board.Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon's proprietary Capture and","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/polyrizon-launches-preclinical-studies-intranasal-115100658.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PLRZ"],"gpt_icon":0},{"id":"2518772335","title":"Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2518772335","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518772335?lang=en_us&edition=fundamental","pubTime":"2025-03-12 04:27","pubTimestamp":1741724820,"startTime":"0","endTime":"0","summary":"Raanana, Israel, March  11, 2025  (GLOBE NEWSWIRE) --  Polyrizon Ltd. (Nasdaq: PLRZ) (the \"Company\" or \"Polyrizon\"), a development stage biotech company specializing in the development of innovative i","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/11/3041024/0/en/Polyrizon-Ltd-Files-Annual-Report-on-Form-20-F-for-the-Fiscal-Year-Ended-December-31-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"gpt_icon":0},{"id":"2518223720","title":"Polyrizon Initiates Preclinical Studies for Intranasal Naloxone Targeting Opioid Overdose Based on Its Innovative T&T Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2518223720","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518223720?lang=en_us&edition=fundamental","pubTime":"2025-03-10 19:47","pubTimestamp":1741607220,"startTime":"0","endTime":"0","summary":"Raanana, Israel, March 10, 2025  -- Polyrizon Ltd.  , a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today the initiation of preclinical studies for intranasal Naloxone, a life-saving opioid overdose treatment.The study will be conducted in collaboration with Professor Fabio Sonvico, Associate Professor at the Department of Food and Drug of the University of Parma  a leading expert in the development of intranasal and pulmonary drug delivery solutions and a member of the Company’s Scientific Advisory Board.Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain TM, or C&C, hydrogel t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/polyrizon-initiates-preclinical-studies-intranasal-114700597.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PLRZ"],"gpt_icon":0},{"id":"2507649876","title":"Polyrizon files divisional patent application with Israel Patent Office","url":"https://stock-news.laohu8.com/highlight/detail?id=2507649876","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507649876?lang=en_us&edition=fundamental","pubTime":"2025-01-30 19:05","pubTimestamp":1738235119,"startTime":"0","endTime":"0","summary":"Polyrizon (PLRZ) announced the filing of a divisional patent application with the Israel Patent Office for its Trap & Target platform technology. T...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/polyrizon-files-divisional-patent-application-with-israel-patent-office?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/polyrizon-files-divisional-patent-application-with-israel-patent-office?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PLRZ"],"gpt_icon":0},{"id":"2507646717","title":"Polyrizon Announces Filing of Divisional Patent Application for Its Innovative Trap & Target™ (T&T) Intranasal Drug Delivery Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2507646717","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507646717?lang=en_us&edition=fundamental","pubTime":"2025-01-30 18:55","pubTimestamp":1738234500,"startTime":"0","endTime":"0","summary":"Raanana, Israel, Jan. 30, 2025  -- Polyrizon Ltd.  , a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the filing of a divisional patent application with the Israel Patent Office for its Trap & Target (T&T) platform technology. This application focuses exclusively on protecting the Company’s advanced intranasal drug delivery system, which is designed to enhance the effectiveness of medications by increasing their residence time and ensuring close contact with mucosal tissues and aligns with the Company’s recently announced U.S. patent application which encompasses key aspects of Polyrizon’s two core platform technologies: Capture and Contain (C&C), a nasal blocker technology, and Trap and Target (T&T), designed for advanced nasal drug delivery.The T&T platform represents a significant advancement in intranasal drug delivery, offering a novel approach to improving the bioavailability of active pharmaceutical ingredien","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/polyrizon-announces-filing-divisional-patent-105500729.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PLRZ"],"gpt_icon":0},{"id":"2505842091","title":"BRIEF-Polyrizon Commences Gmp Manufacturing Preliminary Process","url":"https://stock-news.laohu8.com/highlight/detail?id=2505842091","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505842091?lang=en_us&edition=fundamental","pubTime":"2025-01-23 19:55","pubTimestamp":1737633304,"startTime":"0","endTime":"0","summary":"BRIEF-Polyrizon Commences Gmp Manufacturing Preliminary ProcessJan 23 (Reuters) - Polyrizon Ltd PLRZ.O:POLYRIZON COMMENCES GMP MANUFACTURING PRELIMINARY PROCESS FOR ITS PL-14 ALLERGY BLOCKER IN PREPAR","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250123:nTUA48GNYT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ"],"gpt_icon":0},{"id":"2505209987","title":"Polyrizon Commences Gmp Manufacturing Preliminary Process for Its Pl-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2505209987","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505209987?lang=en_us&edition=fundamental","pubTime":"2025-01-23 19:40","pubTimestamp":1737632400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250123:nTUA48GNYT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PLRZ"],"gpt_icon":0},{"id":"2505173099","title":"Polyrizon Commences GMP Manufacturing Preliminary Process for its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2505173099","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505173099?lang=en_us&edition=fundamental","pubTime":"2025-01-23 19:40","pubTimestamp":1737632400,"startTime":"0","endTime":"0","summary":"Eurofins CDMO Amatsiaquitaine S.A.S., the GMP manufacturer, to support Polyrizon in future commercialization efforts. Raanana, Israel, Jan. 23, 2025  -- Polyrizon Ltd. , a development stage biotech company specializing in the development of innovative intranasal hydrogels, announces today it has commenced preliminary work related to the Good Manufacturing Practice  manufacturing process for its PL-14 allergy blocker in preparation for its planned 2025 clinical trial. The company works closely with Eurofins CDMO, having recently entered into a manufacturing agreement with Eurofins CDMO Amatsiaquitaine S.A.S.Polyrizon is progressing with preparations for its planned 2025 clinical trial. The designated manufacturing facility is equipped to meet the clinical trial material  requirements, ensuring high-quality production and compliance with regulatory standards.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/polyrizon-commences-gmp-manufacturing-preliminary-114000593.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4134","BK4123","CDMO","PL","CTM","BK4139","PLRZ"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":57,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PLRZ\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PLRZ\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PLRZ\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PLRZ\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PLRZ","date":"2025-05-14","current":-0.125533,"percent":1,"low":-29.515607,"twenty":-5.050826,"median":-3.37037,"eighty":-1.421061,"high":-0.125533,"avg":-3.784384,"sd":3.116248,"marketCap":193948},"quantilePoints":[{"date":"2024-10-31","current":-13.097935,"twenty":-22.948538,"median":-13.097935,"eighty":-12.489816,"marketCap":7858761},{"date":"2024-11-08","current":-3.903419,"twenty":-12.692522,"median":-4.690878,"eighty":-4.316449,"marketCap":3891709},{"date":"2024-11-15","current":-2.661127,"twenty":-9.219549,"median":-4.249136,"eighty":-3.530862,"marketCap":2653144},{"date":"2024-11-22","current":-2.985655,"twenty":-4.737156,"median":-3.736612,"eighty":-3.09924,"marketCap":2976698},{"date":"2024-11-29","current":-3.042447,"twenty":-4.451075,"median":-3.375089,"eighty":-3.037515,"marketCap":3033320},{"date":"2024-12-06","current":-3.212824,"twenty":-4.383762,"median":-3.342636,"eighty":-3.042447,"marketCap":3203186},{"date":"2024-12-13","current":-3.375088,"twenty":-4.191157,"median":-3.358862,"eighty":-3.047315,"marketCap":3364963},{"date":"2024-12-20","current":-7.561496,"twenty":-4.383762,"median":-3.375088,"eighty":-3.07146,"marketCap":7538812},{"date":"2024-12-27","current":-5.744141,"twenty":-5.095085,"median":-3.407542,"eighty":-3.090153,"marketCap":5726909},{"date":"2025-01-03","current":-5.938858,"twenty":-6.101122,"median":-3.569805,"eighty":-3.132991,"marketCap":5921041},{"date":"2025-01-10","current":-4.997727,"twenty":-6.159537,"median":-3.796975,"eighty":-3.146231,"marketCap":4982734},{"date":"2025-01-17","current":-6.142316,"twenty":-6.098128,"median":-3.933764,"eighty":-3.167391,"marketCap":6123889},{"date":"2025-01-24","current":-5.889893,"twenty":-6.192801,"median":-4.333277,"eighty":-3.193353,"marketCap":5872223},{"date":"2025-01-31","current":-5.553327,"twenty":-6.125488,"median":-4.527162,"eighty":-3.214122,"marketCap":5536667},{"date":"2025-02-07","current":-4.552045,"twenty":-6.087615,"median":-4.738105,"eighty":-3.227753,"marketCap":4538389},{"date":"2025-02-14","current":-4.711914,"twenty":-6.064471,"median":-4.705652,"eighty":-3.245278,"marketCap":4697778},{"date":"2025-02-21","current":-4.522596,"twenty":-6.049761,"median":-4.627772,"eighty":-3.258259,"marketCap":4509028},{"date":"2025-02-28","current":-3.707687,"twenty":-6.000655,"median":-4.535397,"eighty":-3.316674,"marketCap":3696564},{"date":"2025-03-07","current":-3.460732,"twenty":-5.929065,"median":-4.501561,"eighty":-3.241954,"marketCap":3450350},{"date":"2025-03-14","current":-1.846098,"twenty":-5.873065,"median":-4.396383,"eighty":-3.213473,"marketCap":2852222},{"date":"2025-03-21","current":-1.508371,"twenty":-5.793429,"median":-4.291207,"eighty":-3.160314,"marketCap":2330433},{"date":"2025-03-28","current":-1.353625,"twenty":-5.705978,"median":-3.977976,"eighty":-3.07146,"marketCap":2091350},{"date":"2025-04-04","current":-0.974631,"twenty":-5.536499,"median":-3.903419,"eighty":-3.030526,"marketCap":1505805},{"date":"2025-04-11","current":-0.980061,"twenty":-5.4398,"median":-3.702849,"eighty":-2.640357,"marketCap":1514194},{"date":"2025-04-17","current":-0.985491,"twenty":-5.322255,"median":-3.619184,"eighty":-1.846098,"marketCap":1522583},{"date":"2025-04-25","current":-0.947483,"twenty":-5.174691,"median":-3.5049,"eighty":-1.520317,"marketCap":1463861},{"date":"2025-05-02","current":-0.687943,"twenty":-5.159991,"median":-3.434137,"eighty":-1.353625,"marketCap":1062872},{"date":"2025-05-09","current":-2.602277,"twenty":-5.095085,"median":-3.375088,"eighty":-1.466019,"marketCap":4020518},{"date":"2025-05-14","current":-0.125533,"twenty":-5.050826,"median":-3.37037,"eighty":-1.421061,"marketCap":193948}],"updateTime":1747314625722}}}